Genovac was approached by a client who had a unique technological challenge with respect to the lifespan of synthetic arterial stents. The shortened lifespan of the stent added patient costs by increasing the number of replacement surgeries and stent monitoring. Synthetic arterial stents are required in patients where their own arteries are narrowed or blocked. One major problem of using synthetics stents is that they become blocked through restenosis, the formation of neointimal tissue inside the stent, after a relatively short time. In order to tackle this challenge, Genovac developed a novel way to develop a panel of antibodies that enabled the tethering of endothelial cells to the stents by utilizing VEGFR2. A secondary goal was to develop antibodies that would be specific to different domains.
If you would like to learn more about how we generated a diverse panel of antibodies against all 7 of the VEGFR2 domains, please view our full case study, which can be found on our website.